As mentioned previously, the PI3K/Akt pathway is highly upregulated in head and neck CSCs and therapeutic inhibition of the mechanistic target of rapamycin (mTOR) has shown clinical success in head and neck cancer (97). This evidence concerns the gene MTOR and head and neck cancer.